查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1806157

非處方藥市場按藥品類型、產品形式、分銷管道、年齡層和最終用戶分類－2025-2030 年全球預測

Over The Counter Drugs Market by Drug Type, Product Form, Distribution Channel, Age Group, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

非處方藥 (OTC) 市場規模預計在 2024 年達到 525.2 億美元，在 2025 年達到 567.5 億美元，複合年成長率為 8.68%，在 2030 年達到 865.8 億美元。

主要市場統計數據
基準年2024年 525.2億美元
預計2025年 567.5億美元
預測年份 2030 865.8億美元
複合年成長率（%） 8.68%

非處方藥產業正在經歷前所未有的變革，這得益於消費行為的根本性轉變、監管機構對自我護理的支持以及技術的快速變革時期。雖然實體店分銷曾經是常態，但如今，由於人口結構多樣化，包括注重健康的千禧世代、戰後嬰兒潮世代以及開發中地區新興的中產階級，非處方藥產業正在向多元化發展，包括數位和混合管道。近年來，對預防性健康解決方案的需求激增，迫使製造商不斷創新配方和包裝設計，優先考慮便利性和依從性。

在這種動態環境中，監管機構的職責已發生演變，以適應快速轉換計劃和統一的標籤指南，這些指南優先考慮安全性，同時降低市場准入門檻。因此，市場參與企業正在重新思考其產品開發、供應鏈韌性和全通路行銷的方法。直接面對消費者的廣告和與網紅的夥伴關係正在進一步加速產品知名度的提升，並使利基品牌能夠挑戰現有品牌。

本執行摘要對動盪不安卻充滿機會的非處方藥市場進行了全面的介紹。它概述了關鍵的市場促進因素、關鍵的監管發展以及塑造產業新篇章的策略必要事項。讀者將清楚了解變革趨勢、細分考慮、區域動態、競爭定位以及對持續成長和競爭差異化至關重要的可行建議。

數位醫療的整合、不斷變化的監管環境以及不斷變化的消費者偏好正在推動非處方藥市場的變革

非處方藥市場正在經歷重大變革時期，這得益於數位醫療平台的整合、監管的加強以及消費者期望的不斷變化。遠端醫療應用程式和人工智慧症狀檢查器正在簡化病人歷程，而行動醫療錢包和訂閱模式則將個人化的護理方案直接送到患者家中。此外，虛擬藥局的興起正在顛覆傳統的零售模式，透過數據主導的推薦，實現更快的履約和更深入的消費者互動。

檢驗2025 年美國關稅對非處方藥供應鏈、定價結構和州際貿易動態的累積影響

2025年美國新關稅的實施，正在對非處方藥供應鏈、定價策略和貿易流量產生累積影響。這些針對關鍵藥物成分和包裝零件的關稅，給依賴從現有原料藥（API）進口的製造商帶來了額外的成本壓力。因此，許多公司利潤率受到擠壓，被迫重新評估籌資策略。

透過對非處方藥類型、劑型、通路、年齡層和最終用戶概況進行詳細細分分析，發現成長機會

詳細了解市場細分可以發現跨治療類別、劑型、分銷管道、年齡層和最終用戶概況的定位機會。按藥物類型，感冒、咳嗽和過敏類別細分為抗組織胺、止咳藥和減充血劑，以反映季節性和慢性病的不同需求模式。皮膚科和護膚包括痤瘡藥物、抗真菌藥膏和皮膚保護劑，可滿足美容和臨床使用案例。消化器官系統產品包括從制酸劑到止瀉和瀉藥，可用於一次性和長期胃腸道管理。護耳保健滿足感官舒適和衛生需求，而疼痛緩解包括非類固醇鎮痛藥到局部止痛藥。最後，維生素和補充劑繼續受到預防性健康促進倡導者的強勁需求。

全面的區域視角，重點介紹美洲、中東和非洲以及亞太地區非處方藥產業的市場動態

美洲、中東和非洲以及亞太地區的非處方藥市場動態差異巨大，每個地區都面臨獨特的挑戰和成長催化劑。美洲是一個成熟的市場，人均非處方藥消費量高，並透過在超級市場和直銷數位平台拓展自有品牌不斷創新。在北美，監管協調促進了跨境產品上市，而消費者的期望則側重於循證配方和以生活方式為導向的自我護理。

對影響非處方藥市場格局的主要製藥和保健公司的策略競爭考察

非處方藥市場的競爭格局由全球製藥巨頭、專注於消費者保健的專業製造商以及敏捷的區域企業共同塑造。知名的跨國公司憑藉多元化的產品組合、持續的研發投入以及覆蓋傳統零售和數位通路的廣泛分銷網路，保持著領先地位。跨國公司的規模使其能夠提高採購效率並快速實現全球上市，從而為規模較小的參與企業設置了顯著的進入障礙。

實用且具前瞻性的建議，使行業領導者能夠利用非處方藥市場的新興趨勢

產業領導者若想在不斷發展的非處方藥市場中獲利，必須制定一個多層面的策略議程，將數位創新、監管敏捷性和消費者親密度融為一體。首先，將高階分析技術整合到消費者互動平台中，可實現個人化建議、精準促銷和完善的產品開發藍圖。增強的數據能力還支援動態定價模型，能夠即時響應不斷變化的投入成本和競爭壓力。

我們的綜合研究途徑利用初步研究和二次資料分析，為非處方藥產業提供客觀的見解

研究採用綜合調查方法，將一手資料研究與二手資料分析和嚴格的專家檢驗相結合，以提供可靠、公正的見解。一手資料研究包括與製藥和消費者保健公司高階主管、供應鏈專家、監管顧問和數位健康創新者進行結構化訪談。這些訪談提供了關於策略挑戰、投資重點和新興市場機會的第一手觀點。

總結策略展望，整合關鍵市場促進因素和新興趨勢，塑造非處方藥產業的未來成長軌跡

摘要：非處方藥市場正處於數位顛覆、法規不斷演變和消費者期望不斷變化的關鍵十字路口。關稅壓力、細分市場差異和區域動態的相互作用，凸顯了供應鏈韌性和策略敏捷性的重要性。競爭優勢取決於如何利用數據主導的洞察、與監管機構建立夥伴關係，以及針對不同治療類別和人群提供有針對性的產品。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 消費者對整合虛擬就診和非處方藥購買功能的數位健康平台的偏好日益增加
  • 注重健康的千禧世代推動植物來源和有機非處方補充劑的成長
  • 個人化藥物套餐和訂閱服務在慢性非處方藥使用者中的普及度不斷提升
  • 監管變化對網路藥局含假麻黃堿鼻減充血劑可得性的影響
  • 疫情期間，含有接骨木果、維生素 C 和鋅的免疫支持非處方藥需求激增
  • 擴大自有品牌非處方止痛藥的市場，在價格和針對性疼痛管理處方方面競爭

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章非處方藥市場（依藥品類型）

  • 感冒、咳嗽和過敏藥
    • 抗組織胺藥
    • 止咳藥
    • 鼻減充血劑
  • 皮膚科/護膚
    • 痤瘡治療
    • 抗黴菌藥膏
    • 皮膚屏障
  • 消化器官系統健康
    • 制酸劑
    • 止瀉
    • 瀉藥
  • 眼耳護理
  • 止痛藥
  • 維生素和補充劑

第9章非處方藥市場（依產品類型）

  • 膠囊
  • 液體/糖漿
  • 粉末
  • 噴
  • 栓劑
  • 藥片
  • 外用乳霜/軟膏/凝膠

第10章非處方藥市場（依分銷管道）

  • 離線
    • 藥局和藥局
    • 超級市場和大賣場
  • 線上

第 11 章非處方藥市場（依年齡層）

  • 成人
  • 老年人
  • 孩子們

第 12 章非處方藥市場（依最終使用者）

  • 醫護人員
  • 個人消費者
  • 機構用戶

13.美洲非處方藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 14 章：歐洲、中東和非洲非處方藥市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區非處方藥市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Amneal Pharmaceuticals LLC
    • Aurobindo Pharma Limited
    • Bayer AG
    • Cipla Limited
    • Dr. Reddy's Laboratories Inc.
    • Genomma group
    • GSK plc
    • Hisamitsu Pharmaceutical Co., Inc.
    • Johnson & Johnson Services, Inc.
    • LNK International, Inc.
    • Novartis AG
    • Perrigo Company plc
    • Pfizer Inc.
    • Pierre Fabre SA
    • PL Developments LLC
    • Procter & Gamble Manufacturing Company
    • Reckitt Benckiser LLC
    • Sanofi SA
    • Sun Pharmaceutical Industries Limited
    • Taisho Pharmaceutical Co., Ltd.
    • Teva Pharmaceutical Industries Ltd
    • The Mentholatum Company, Inc.
    • Tris Pharma, Inc.
    • Viatris Inc.
    • Worwag Pharma GmbH & Co. KG
    • Zentiva Group, as

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-436297358D26

The Over The Counter Drugs Market was valued at USD 52.52 billion in 2024 and is projected to grow to USD 56.75 billion in 2025, with a CAGR of 8.68%, reaching USD 86.58 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 52.52 billion
Estimated Year [2025] USD 56.75 billion
Forecast Year [2030] USD 86.58 billion
CAGR (%) 8.68%

The over-the-counter drug sector has entered a period of unprecedented transformation, driven by fundamental shifts in consumer behavior, regulatory support for self-care, and rapid technological advances. Once dominated by brick-and-mortar distribution, the landscape now spans a spectrum of digital and hybrid channels that cater to a demographic blend of health-conscious millennials, aging baby boomers, and emerging middle classes in developing regions. Recent years have seen a surge in demand for preventive wellness solutions, prompting manufacturers to innovate with novel formulations and packaging designs that emphasize convenience and adherence.

Amid this dynamic environment, the role of regulatory agencies has evolved to accommodate expedited switch programs and harmonized labeling guidelines that prioritize safety while reducing barriers for market entry. Consequently, industry participants are recalibrating their approaches to product development, supply chain resilience, and omnichannel marketing. The influence of direct-to-consumer advertising and influencer partnerships has further accelerated product visibility, enabling niche brands to challenge established incumbents.

This executive summary provides a cohesive introduction to the volatile yet opportunity-rich over-the-counter drug landscape. It outlines the key market drivers, pivotal regulatory developments, and strategic imperatives shaping the industry's next chapter. Readers will gain clarity on transformative trends, segmentation insights, regional dynamics, competitive positioning, and actionable recommendations essential for sustained growth and competitive differentiation.

Transformative Shifts Reshaping the Over-the-Counter Drug Landscape Driven by Digital Health Integration, Regulatory Changes, and Changing Consumer Preferences

The over-the-counter drug market is undergoing profound transformative shifts, propelled by the integration of digital health platforms, intensified regulatory changes, and evolving consumer expectations. Telemedicine applications and AI-driven symptom checkers now streamline the purchase journey, while mobile health wallets and subscription models offer personalized care regimens directly to patients' homes. Moreover, the proliferation of virtual pharmacies has disrupted traditional retail models, enabling faster fulfillment and deeper consumer engagement through data-driven recommendations.

Parallel to these digital innovations, regulatory agencies across key markets have implemented reforms to expedite switch-to-OTC processes and standardize safety protocols. These changes have reduced the time and cost associated with bringing new therapies to over-the-counter status, encouraging firms to allocate greater resources to clinical research and real-world evidence generation. In turn, the market has seen an influx of once-prescription treatments, expanding therapeutic options in dermatology, gastrointestinal health, and respiratory care.

Concurrently, consumer preferences are shifting toward clean-label formulations, sustainable packaging, and transparent sourcing practices. Health-conscious shoppers are increasingly scrutinizing ingredient lists and favoring brands that demonstrate environmental stewardship. This confluence of digital advancement, regulatory alignment, and heightened consumer awareness is redefining competitive advantage in the OTC drug arena, compelling stakeholders to adopt agile strategies that balance innovation with compliance and brand authenticity.

Examining the Cumulative Impact of United States Tariffs in 2025 on Over-the-Counter Drug Supply Chains, Pricing Structures, and Interstate Trade Dynamics

The implementation of new United States tariff measures in 2025 has exerted a cumulative impact on over-the-counter drug supply chains, pricing strategies, and trade flows. These levies, targeting key pharmaceutical ingredients and packaging components, have introduced additional cost pressures on manufacturers reliant on imported active pharmaceutical ingredients (APIs) from established chemical hubs. As a result, many companies have experienced margin compression and have been compelled to reassess procurement strategies.

In response, stakeholders have accelerated efforts to develop localized API production capabilities and form strategic alliances with domestic suppliers. Inventory management practices have also adapted, with firms increasing safety stock levels to buffer against tariff-induced disruptions. Additionally, dynamic pricing models have emerged, enabling swift adjustment of consumer-facing prices to reflect input cost fluctuations while preserving affordability.

Beyond supply chain realignment, the tariff landscape has stimulated a broader reevaluation of global sourcing footprints. Companies are diversifying alternative manufacturing locations across Asia-Pacific and Latin America to mitigate exposure. These strategic shifts are enhancing resilience but require careful navigation of regulatory approvals and quality standards. Ultimately, the tariff environment of 2025 has catalyzed a wave of strategic realignments that are redefining competitive positioning and supply chain configurations within the over-the-counter drug market.

Unlocking Growth Opportunities Through In-Depth Segmentation Analysis of Over-the-Counter Drug Types, Forms, Channels, Age Groups, and End-User Profiles

A nuanced understanding of market segmentation reveals targeted opportunities across therapeutic categories, dosage forms, distribution channels, demographic cohorts, and end-user profiles. In the realm of drug types, the cold, cough, and allergy category subdivides into antihistamines, cough suppressants, and decongestants, reflecting differentiated demand patterns across seasonal and chronic conditions. Dermatology and skin care encompasses acne treatments, antifungal creams, and skin protectants, catering to both cosmetic and clinical use cases. Digestive health products range from antacids to anti-diarrheal remedies and laxatives, responding to episodic and long-term gastrointestinal management. Eye and ear care solutions address sensory comfort and hygiene needs, while pain relief medications span nonsteroidal analgesics and topical analgesic formulations. Finally, vitamins and supplements continue to enjoy robust demand from preventive wellness advocates.

Product form segmentation further illuminates consumer preferences, encompassing capsules, liquids and syrups, powders, sprays, suppositories, tablets and pills, as well as topical creams, ointments, and gels. Each format aligns with specific administration considerations, such as pediatric dosing comfort, geriatric swallowing ease, or localized delivery.

Distribution channels exhibit a bifurcation between offline and online pathways, with offline channels structured around pharmacies, drug stores, supermarkets, and hypermarkets that emphasize immediate accessibility. Online channels leverage e-commerce platforms and direct-to-consumer portals, facilitating subscription offerings and telehealth integration.

Demographic segmentation underscores divergent needs among adult, geriatric, and pediatric populations, each demanding tailored formulations, dosage strengths, and packaging ergonomics. Similarly, end-user segmentation distinguishes healthcare professionals prescribing or recommending OTC therapies, individual consumers driving retail purchases, and institutional users such as hospitals, long-term care facilities, and corporate wellness programs procuring products in bulk. This layered segmentation framework enables precision targeting of product portfolios, marketing strategies, and supply chain allocations.

Comprehensive Regional Perspective Highlighting Market Dynamics Across Americas, Europe Middle East & Africa, and Asia-Pacific Over-the-Counter Drug Sectors

Regional dynamics in the over-the-counter drug market vary substantially across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting unique challenges and growth catalysts. In the Americas, a mature market characterized by high per-capita OTC consumption continues to innovate through private-label expansions in supermarkets and direct-to-consumer digital platforms. Regulatory harmonization efforts in North America facilitate cross-border product launches, while consumer expectations center on evidence-based formulations and lifestyle-oriented self-care routines.

The Europe Middle East & Africa region encompasses a broad array of regulatory environments, distribution infrastructures, and economic conditions. Western Europe's advanced regulatory frameworks and robust pharmacy networks support rapid adoption of novel OTC switches, whereas emerging economies in Eastern Europe and the Middle East prioritize affordability and access through generic alternatives and multinational partnerships. In Africa, the rise of mobile health initiatives and localized manufacturing hubs is gradually improving product availability and driving interest in mobile pharmacies and e-health platforms.

In contrast, Asia-Pacific stands out as the fastest-growing regional market, fuelled by rising disposable incomes, urbanization, and expanding healthcare access. Countries in East and Southeast Asia are witnessing surges in online pharmacy usage and cross-border purchases, while South Asia's dense population base accelerates demand for cost-effective self-care solutions. Collaborative ventures between domestic innovators and global players are enhancing technology transfer, creating a dynamic environment for product innovation and regulatory advancement.

Strategic Competitive Insights into Leading Pharmaceutical and Consumer Healthcare Companies Shaping the Over-the-Counter Drug Market Landscape

The competitive landscape of the over-the-counter drug market is shaped by global pharmaceutical giants, specialized consumer healthcare manufacturers, and agile regional players. Prominent multinational corporations maintain leadership through diversified portfolios, continuous R&D investment, and expansive distribution networks that span both traditional retail and digital channels. Their scale enables procurement efficiencies and rapid global launch capabilities, creating significant barriers for smaller entrants.

Meanwhile, niche innovators and private-label purveyors have carved out differentiation by focusing on natural and botanical formulations, premium wellness positioning, and direct engagement with consumer communities. These companies leverage e-commerce analytics and personalized marketing campaigns to gain traction in specific segments such as dermatology, digestive health, and nutritional supplements.

Regional champions in emerging markets are also gaining prominence by tailoring product offerings to local preferences and regulatory frameworks. Some have optimized cost structures through regional manufacturing hubs and strategic alliances with contract development and manufacturing organizations. Collectively, these competitive approaches underscore the importance of agility, brand authenticity, and supply chain resilience in securing sustainable market share.

Practical and Forward-Looking Recommendations Empowering Industry Leaders to Capitalize on Emerging Trends in Over-the-Counter Drug Markets

Industry leaders seeking to capitalize on the evolving over-the-counter drug market must adopt a multipronged strategic agenda that blends digital innovation, regulatory agility, and consumer intimacy. Firstly, integrating advanced analytics into consumer engagement platforms will enable personalized recommendations, targeted promotions, and refined product development roadmaps. Enhanced data capabilities will also support dynamic pricing models that adjust in real time to input cost fluctuations and competitive pressures.

Secondly, firms should pursue localized manufacturing partnerships and invest in onshore API production to mitigate tariff exposure and reduce supply chain complexity. Developing contingency plans with alternate suppliers and maintaining strategic stock reserves will further enhance resilience against geopolitical disruptions.

Thirdly, expanding into adjacent wellness categories-such as nutraceuticals, functional foods, and digital therapeutics-can unlock cross-selling synergies and attract health-oriented consumers. Collaborations with telehealth providers and integration with health monitoring devices will position organizations at the intersection of prevention and treatment.

Finally, embedding sustainability principles across product life cycles, from ingredient sourcing to packaging design, will resonate with environmentally conscious consumers and align with emerging regulatory mandates. By prioritizing these actionable recommendations, industry leaders can strengthen market positioning and drive long-term, profitable growth.

Comprehensive Research Approach Leveraging Primary Interviews and Secondary Data Analysis to Deliver Unbiased Insights into Over-the-Counter Drug Sector

This research draws upon a comprehensive methodology that synthesizes primary interviews, secondary data analysis, and rigorous expert validation to ensure robust and unbiased insights. Primary research involved structured interviews with senior executives from pharmaceutical and consumer healthcare companies, supply chain specialists, regulatory consultants, and digital health innovators. These conversations provided firsthand perspectives on strategic challenges, investment priorities, and emerging market opportunities.

Secondary research encompassed a systematic review of regulatory filings, industry periodicals, corporate annual reports, and technical white papers. Publicly available data from government agencies and trade associations was triangulated with proprietary sources to enhance data accuracy and contextual depth. Quantitative analyses employed advanced statistical techniques to identify consumption patterns, channel shifts, and demographic influences across multiple geographies.

Finally, an expert validation process convened cross-functional industry advisors to critique preliminary findings, refine segmentation frameworks, and vet strategic recommendations. This iterative approach ensured that conclusions reflect the latest market developments and operational realities, offering decision-makers a credible foundation for strategic planning.

Concluding Strategic Perspectives Synthesizing Key Market Drivers and Emerging Trends Shaping Future Growth Trajectories in Over-the-Counter Drug Industry

In summary, the over-the-counter drug market stands at a pivotal juncture defined by digital disruption, regulatory evolution, and shifting consumer expectations. The interplay of tariff pressures, segmentation nuances, and regional dynamics underscores the importance of supply chain resilience and strategic agility. Competitive success will hinge on the ability to harness data-driven insights, cultivate regulatory partnerships, and deliver targeted offerings across therapeutic categories and demographic groups.

As market participants navigate this complex environment, those who embrace innovation in manufacturing, distribution, and marketing will secure the greatest advantage. Proactive investments in localized production, sustainable practices, and consumer personalization will strengthen brand loyalty and foster long-term growth. By internalizing the strategic recommendations outlined herein, organizations can chart a clear path forward and translate market intelligence into differentiated value propositions.

Ultimately, the insights presented in this summary provide a strategic roadmap for executives, investors, and stakeholders aiming to capitalize on the accelerating momentum within the over-the-counter drug sector. The confluence of emerging technologies, consumer empowerment, and regulatory reforms offers a fertile landscape for innovation and competitive advancement.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Increasing consumer preference for digital health platforms integrating virtual consultations with OTC medication purchases
  • 5.2. Accelerated growth in plant-based and organic OTC supplements driven by wellness-focused millennial demographics
  • 5.3. Rising adoption of personalized dosage packaging and subscription services for chronic OTC medication users
  • 5.4. Impact of regulatory shifts on accessibility of pseudoephedrine-containing decongestants in online pharmacies
  • 5.5. Surge in demand for immune support OTC products fortified with elderberry, vitamin C, and zinc during viral seasons
  • 5.6. Expansion of private label OTC pain relievers competing on price and targeted pain management formulations

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Over The Counter Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Cold, Cough, & Allergy Medications
    • 8.2.1. Antihistamines
    • 8.2.2. Cough Suppressants
    • 8.2.3. Decongestants
  • 8.3. Dermatology & Skin Care
    • 8.3.1. Acne Treatments
    • 8.3.2. Antifungal Creams
    • 8.3.3. Skin Protectants
  • 8.4. Digestive Health
    • 8.4.1. Antacids
    • 8.4.2. Anti-diarrheal
    • 8.4.3. Laxatives
  • 8.5. Eye & Ear Care
  • 8.6. Pain Relief Medications
  • 8.7. Vitamins & Supplements

9. Over The Counter Drugs Market, by Product Form

  • 9.1. Introduction
  • 9.2. Capsules
  • 9.3. Liquids/Syrups
  • 9.4. Powders
  • 9.5. Sprays
  • 9.6. Suppositories
  • 9.7. Tablets/Pills
  • 9.8. Topical Creams/Ointments/Gels

10. Over The Counter Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
    • 10.2.1. Pharmacies & Drug Stores
    • 10.2.2. Supermarkets & Hypermarkets
  • 10.3. Online

11. Over The Counter Drugs Market, by Age Group

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Over The Counter Drugs Market, by End-user

  • 12.1. Introduction
  • 12.2. Healthcare Professionals
  • 12.3. Individual Consumers
  • 12.4. Institutional Users

13. Americas Over The Counter Drugs Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Over The Counter Drugs Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Over The Counter Drugs Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Amneal Pharmaceuticals LLC
    • 16.3.2. Aurobindo Pharma Limited
    • 16.3.3. Bayer AG
    • 16.3.4. Cipla Limited
    • 16.3.5. Dr. Reddy's Laboratories Inc.
    • 16.3.6. Genomma group
    • 16.3.7. GSK plc
    • 16.3.8. Hisamitsu Pharmaceutical Co., Inc.
    • 16.3.9. Johnson & Johnson Services, Inc.
    • 16.3.10. LNK International, Inc.
    • 16.3.11. Novartis AG
    • 16.3.12. Perrigo Company plc
    • 16.3.13. Pfizer Inc.
    • 16.3.14. Pierre Fabre S.A
    • 16.3.15. PL Developments LLC
    • 16.3.16. Procter & Gamble Manufacturing Company
    • 16.3.17. Reckitt Benckiser LLC
    • 16.3.18. Sanofi S.A.
    • 16.3.19. Sun Pharmaceutical Industries Limited
    • 16.3.20. Taisho Pharmaceutical Co., Ltd.
    • 16.3.21. Teva Pharmaceutical Industries Ltd
    • 16.3.22. The Mentholatum Company, Inc.
    • 16.3.23. Tris Pharma, Inc.
    • 16.3.24. Viatris Inc.
    • 16.3.25. Worwag Pharma GmbH & Co. KG
    • 16.3.26. Zentiva Group, a.s.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. OVER THE COUNTER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. OVER THE COUNTER DRUGS MARKET: RESEARCHAI
  • FIGURE 26. OVER THE COUNTER DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. OVER THE COUNTER DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 28. OVER THE COUNTER DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. OVER THE COUNTER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DECONGESTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DECONGESTANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ACNE TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ACNE TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIFUNGAL CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIFUNGAL CREAMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SKIN PROTECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SKIN PROTECTANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTACIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTI-DIARRHEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTI-DIARRHEAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY EYE & EAR CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY EYE & EAR CARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PAIN RELIEF MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PAIN RELIEF MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LIQUIDS/SYRUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LIQUIDS/SYRUPS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TABLETS/PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TABLETS/PILLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS/GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS/GELS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PHARMACIES & DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PHARMACIES & DRUG STORES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPERMARKETS & HYPERMARKETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPERMARKETS & HYPERMARKETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INSTITUTIONAL USERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INSTITUTIONAL USERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 149. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 167. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 170. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 185. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 187. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 188. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 189. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 190. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 241. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 244. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 245. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 246. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 247. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 248. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 249. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 250. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 251. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 255. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 257. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 259. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 263. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 265. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 267. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 269. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 271. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 272. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 273. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 275. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 276. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 277. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 280. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 281. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 283. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 284. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 285. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 286. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 287. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 289. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 291. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 293. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 294. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 295. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 299. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 301. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 303. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 304. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
  • TABLE 305. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 307. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 308. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 309. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 311. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 312. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 313. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 315. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 317. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
  • TABLE 319. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
  • TABLE 321. SPAIN OVER THE COUNTER DRUGS MARKE